An Open-Label, Multi-Center, Expanded Access Program With Eribulin for the Treatment of Advanced Breast Cancer Refractory
Expanded access is currently available for this treatment.
Verified March 2013 by Eisai Inc.
Information provided by (Responsible Party):
First received: October 1, 2010
Last updated: March 3, 2013
Last verified: March 2013
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||Expanded access is currently available for this treatment.|
|Estimated Study Completion Date:||No date given|
|Estimated Primary Completion Date:||March 2012 (Final data collection date for primary outcome measure)|